Labcorp (LH) Expected to Post Quarterly Earnings on Wednesday

Key Points

• Labcorp is expected to report Q3 2026 results before the market opens Wednesday, October 28. Analysts forecast earnings of $4.64 per share on $3.76 billion in revenue, while the company’s full-year EPS guidance is $18.10–$18.55.
• In the prior quarter, Labcorp exceeded expectations with $4.99 EPS and $3.73 billion in revenue; revenue increased 5.8% year over year.
• Analysts remain broadly bullish, with eight Buy ratings and three Holds and a consensus price target of $337.73. The stock recently opened at $322.90, while insiders have sold 8,593 shares worth approximately $2.73 million over the past quarter.

Labcorp (NYSE:LH - Get Free Report) is anticipated to release its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect Labcorp to announce earnings of $4.64 per share and revenue of $3.76 billion for the quarter. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Individuals can check the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 9:00 AM ET.

Labcorp (NYSE:LH - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, topping analysts' consensus estimates of $4.78 by $0.21. The firm had revenue of $3.73 billion for the quarter, compared to analysts' expectations of $3.71 billion. Labcorp had a return on equity of 16.74% and a net margin of 6.99%. Labcorp's revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $4.35 EPS. On average, analysts expect Labcorp to post $18.32 EPS for the current fiscal year and $19.69 EPS for the next fiscal year.

Labcorp Price Performance

NYSE LH opened at $322.90 on Wednesday. The stock's 50-day moving average price is $320.55 and its two-hundred day moving average price is $289.98. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. The company has a market cap of $26.19 billion, a PE ratio of 26.71, a PEG ratio of 1.82 and a beta of 0.87. Labcorp has a 1 year low of $244.52 and a 1 year high of $341.80.

Insider Buying and Selling at Labcorp

In other Labcorp news, Director Kerrii Anderson sold 3,000 shares of the company's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $318.02, for a total value of $954,060.00. Following the transaction, the director owned 6,563 shares in the company, valued at approximately $2,087,165.26. This represents a 31.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amy Summy sold 924 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $306.74, for a total transaction of $283,427.76. Following the completion of the sale, the executive vice president owned 6,956 shares of the company's stock, valued at approximately $2,133,683.44. The trade was a 11.73% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 8,593 shares of company stock worth $2,733,295. 0.84% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have commented on LH shares. UBS Group raised their target price on shares of Labcorp from $361.00 to $380.00 and gave the stock a "buy" rating in a report on Friday, September 11th. Robert W. Baird set a $352.00 price target on shares of Labcorp in a report on Friday, July 31st. Truist Financial upped their price target on shares of Labcorp from $350.00 to $365.00 and gave the company a "buy" rating in a research report on Monday, September 21st. Mizuho set a $355.00 price target on shares of Labcorp in a research report on Monday, August 10th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Labcorp from $330.00 to $360.00 and gave the stock an "overweight" rating in a research note on Monday, August 3rd. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $337.73.

About Labcorp

Labcorp NYSE: LH, formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women's health testing, genetic testing, pathology services and other laboratory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.